Dyne Therapeutics misses by $0.01, reports no revenue (26.00 +0.17)
- Reports Q1 EPS of ($0.81), $0.01worse than the ($0.80) FactSet consensus estimate; no revenue.
- Dyne anticipates reporting data from multiple, higher dose cohorts from both the ACHIEVE and DELIVER trials in the second half of 2024 with the goal of initiating registrational cohorts by the end of 2024.
- Cash, cash equivalents and marketable securities were $453.5 million as of March 31, 2024. In addition, subsequent to March 31, 2023, the company received $24.3 million from the sale of stock through its "at the market" offering program. The Company's cash, cash equivalents and marketable securities are anticipated to fund operations through 2025.